Beigene, Ltd.

Beigene Switzerland Gmbh

Honeywell International Inc.

Jing Song

Tong Zhang

Kang Li

Qi Liu

Hao Peng

Lanlan Xu

Min Wei

Lai Wang

Lusong Luo

Changyou Zhou

Zhiyu Tang

Guoliang Zhang

Yucheng Li

Zhiying Ren

Yanshen Kang

Peng Liu

Haifeng Wang

Zhiwei Wang

Wei Cui

Lin Wang

Nan Hu

Yunhang Guo

Hexiang Wang

Bo Ren

Patrick Glaze

In some examples, a system includes a receiver configured to receive temperature data for a region of airspace from a data source external to the vehicle. The system also includes processing circuitry configured to determine one or more moisture values for the region of airspace based on radar returns received by a weather radar onboard the vehicle. The processing circuitry is further configured to determine a potential for icing at a location within the region of airspace based on the one or more moisture values and further based on the temperature data received from the data source. The processing circuitry is also configured to generate an output based on the determined potential for icing at the location.

Icing detection using temperature data from an external data source

Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a targeted therapy agent. Also, disclosed a pharmaceutical combination comprising a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor, or a targeted therapy agent and the use thereof.

Treatment of B cell cancers using a combination comprising Btk inhibitors

Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.

Anti-PD1 antibodies and their use as therapeutics and diagnostics

Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy. The pharmaceutical combination comprises a humanized antagonist monoclonal antibody against PD- and a RAF inhibitor. Also disclosed herein is a combination for use in the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject a therapeutically effective amount of a humanized antagonist monoclonal antibody against PD-1 and a therapeutically effective amount of a RAF inhibitor.

Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer

Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) ligand (PD-L1) and inhibit PD-L1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD-L1-mediated functions.

Anti-PD-L1 antibodies and their use as therapeutics and diagnostics

In one example, this disclosure is directed to a system configured to detect inclement weather in the travel path of a vehicle, determine a recommended maneuver to avoid the inclement weather, and determine the feasibility of the recommended maneuver with respect to any nearby vehicles.

Connected weather radar

Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a PARP inhibitor, particularly, (R)-2-fluoro-10a-methyl-7,8,9,10,10a,11-hexahydro-5,6,7a,11-tetraazacyclohepta[def]cyclopenta[a]fluoren-4(5H)-one, a sesqui-hydrate thereof, or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a chemotherapeutic agent. Also, disclosed a pharmaceutical combination comprising a PARP inhibitor, particularly, (R)-2-fluoro-10a-methyl-7,8,9,10,10a,11-hexahydro-5,6,7a,11-tetraazacyclohepta[def]cyclopenta[a]fluoren-4(5H)-one, a sesqui-hydrate thereof, or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor, or a chemotherapeutic agent and the use thereof.

Treatment cancers using a combination comprising PARP inhibitors

Growing community of inventors

Beijing, China

Jing Song